Tenax <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Loss of $10.9M, Up from $3.6M in Q2 2024; Increased R&D and G&A Expenses Cited
Tenax Therapeutics Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $10.9 million, compared to a net loss of $3.6 million in the same period in 2024. The company's General and Administrative (G&A) expenses increased due to a $3.6 million rise in non-cash stock-based compensation expense, attributed to option grants from December 2024 and May 2025. Additionally, salaries, performance-based compensation, legal, and professional fees experienced an uptick. The research and development (R&D) expenses for the second quarter of 2025 reached $6.1 million, up from $2.3 million in 2024. This increase was largely due to heightened clinical development costs for the Phase 3 LEVEL study and the initiation of the LEVEL-2 study, alongside an increase in R&D personnel costs. Tenax Therapeutics has made significant strides in its corporate operations, with plans to initiate the second Phase 3 study, LEVEL-2, this year. The company has expanded its operations team to oversee the LEVEL program, adding new leadership in Clinical Operations, Data Management, Pharmacovigilance, and Quality Assurance. As of June 30, 2025, Tenax holds $105.5 million in cash and cash equivalents, which is expected to fund the company through 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-25-009510), on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.